Neutravera (Magnesium Chloride Hexahydrate, Sodium Chloride, Calcium Chloride Dihydrate, Glucose Monohydrate, So)

Neutravera is used to address fluid and electrolyte disturbances in clinical settings.

• Hypovolemia: restores circulating volume and prevents circulatory collapse.
• Electrolyte depletion: replenishes magnesium, calcium, sodium and glucose levels to correct imbalances.
• Peritoneal dialysis: provides a balanced electrolyte solution for dialysis exchanges.
• Post‑operative care: supports fluid balance after major surgery.
• Trauma resuscitation: supplies essential ions and energy substrate during acute blood loss.

• Neutravera delivers magnesium, calcium, sodium ions and glucose directly into the peritoneal cavity. The dissolved salts dissociate, increasing extracellular concentrations of these electrolytes, which are then absorbed across the peritoneal membrane into the systemic circulation. Magnesium and calcium act as cofactors in numerous enzymatic reactions, while sodium contributes to osmotic balance and plasma volume. Glucose serves as an immediate energy source and facilitates osmotic water movement, aiding rapid fluid replacement.

Neutravera may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Transient abdominal discomfort: mild pain or bloating at the infusion site.
• Mild hypermagnesemia: elevated serum magnesium without clinical symptoms.
• Mild hypernatremia: slight increase in serum sodium levels.
• Local irritation: redness or irritation at the injection site.

Serious or Rare Side Effects

• Severe hypermagnesemia: can lead to hypotension, bradycardia, or cardiac arrhythmia.
• Severe hypercalcemia: may cause muscle weakness, confusion, or renal impairment.
• Anaphylactic reaction: sudden onset of hives, airway swelling, or hypotension.
• Fluid overload: pulmonary edema due to excessive volume administration.

When using Neutravera, several precautions should be observed to ensure patient safety and product integrity.

• Assess baseline electrolyte status: obtain serum magnesium, calcium, and sodium levels before infusion.
• Monitor electrolytes during therapy: check serum concentrations regularly to avoid over‑correction.
• Use caution in renal impairment: reduced clearance may increase risk of electrolyte accumulation.
• Infuse at controlled rate: avoid rapid administration to prevent fluid overload and hemodynamic shifts.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Neutravera can interact with other medicines that affect electrolyte balance or cardiovascular function.

Major Interactions (Avoid)

• Concurrent magnesium‑containing products: may cause additive hypermagnesemia.
• Calcium channel blockers: increased calcium load can enhance cardiovascular effects.
• High‑dose insulin therapy: shifts potassium and may exacerbate electrolyte disturbances.

Moderate Interactions (Monitor Closely)

• Loop diuretics: promote loss of electrolytes, requiring closer monitoring.
• ACE inhibitors or ARBs: may affect renal handling of sodium and potassium.
• Anticoagulants used during peritoneal dialysis: monitor for bleeding risk due to fluid shifts.